Clinical Trial Update: A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma [Phase 2]

View source ↗

Summary

This is a Phase II clinical trial evaluating a combination of tremelimumab, durvalumab, gemcitabine, and cisplatin for locally advanced unresectable or metastat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Hepatocellular-cholangiocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Durvalumab (durvalumab)
• Gemcitabine (Gemcitabine)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Mehmet Akce | Conditions: Combined Hepatocellular and Cholangiocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING